MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

25.41 -3.68

Overview

Share price change

24h

Current

Min

25.03

Max

27.12

Key metrics

By Trading Economics

Income

-3.8M

-81M

EPS

-0.88

Profit margin

-18,560.15

Employees

437

EBITDA

-6.9M

-94M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+187.45% upside

Dividends

By Dow Jones

Next Earnings

8 May 2025

Market Stats

By TradingEconomics

Market Cap

21M

3.2B

Previous open

29.09

Previous close

25.41

News Sentiment

By Acuity

50%

50%

173 / 385 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 Apr 2025, 22:42 UTC

Major Market Movers

Peabody Energy Shares Climb on Trump Executive Orders Boosting Coal Industry

8 Apr 2025, 22:35 UTC

Earnings
Major Market Movers

Cal-Maine Foods Shares Fall As Justice Dept Probes Egg Prices

8 Apr 2025, 21:30 UTC

Earnings

Cal-Maine Foods Cooperating With Justice Dept Probe Into Egg Price Increases -- Update

8 Apr 2025, 21:21 UTC

Earnings

Cal-Maine Foods Cooperating With Justice Dept Probe into Egg Price Increases

9 Apr 2025, 00:00 UTC

Top News

Trump's Tariffs Put Fed Chair Powell in a 'No-Win Situation' -- WSJ

8 Apr 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Apr 2025, 23:45 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

8 Apr 2025, 23:43 UTC

Market Talk

Lithium Oversupply Weighs on Price Outlook -- Market Talk

8 Apr 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Woolworths' Rivals Have Other Options to Source Ready Meals, ACCC Says

8 Apr 2025, 23:42 UTC

Market Talk

Gold Falls on Possible Unwinding of Long Positions to Raise Cash -- Market Talk

8 Apr 2025, 23:42 UTC

Acquisitions, Mergers, Takeovers

Beak & Johnston Makes Ready Meals, Pastries for Wholesale, Retail

8 Apr 2025, 23:41 UTC

Acquisitions, Mergers, Takeovers

Woolworths' Acquisition Unlikely to Have Substantial Anti-Competitive Effect, ACCC Says

8 Apr 2025, 23:40 UTC

Acquisitions, Mergers, Takeovers

Australian Competition and Consumer Commission: Will Not Oppose Transaction

8 Apr 2025, 23:39 UTC

Acquisitions, Mergers, Takeovers

Australian Competition Regulator to Allow Woolworths' Acquisition of Beak & Johnston

8 Apr 2025, 23:21 UTC

Acquisitions, Mergers, Takeovers

U.S. Steel: $75 per Shr That the Ancora 'Plan' Proposes Is Really an Unrealistic, Distant Future Value Pipedream Rooted Firmly in Fiction >X

8 Apr 2025, 23:21 UTC

Acquisitions, Mergers, Takeovers

U.S. Steel: Stockholders Should Be Very Skeptical of Ancora's 'Plan' or That Their Nominees Could or Would Vigorously Fight for the Nippon Steel Deal >X

8 Apr 2025, 21:26 UTC

Top News

When Coffee Mate Made a 'White Lotus' PiƱa Colada Creamer, It Had No Idea How the Season Would End -- WSJ

8 Apr 2025, 21:26 UTC

Earnings

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

8 Apr 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Peabody Energy: Remains in Conversation With Anglo Amer to Better Understand Impacts of Event, Preserving All Rights and Protections Under Purchase Agreements >BTU

8 Apr 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Peabody Energy: Following Ignition Event Last Week at Anglo Amer's Moranbah North Mine, Reviewing Options Related to Acquisition of Steelmaking Coal Assets From Anglo Amer >BTU

8 Apr 2025, 21:06 UTC

Top News

Stocks Are in Turmoil, but Treasury Yields Are Stubbornly High -- Update

8 Apr 2025, 20:50 UTC

Top News

Harley-Davidson Seeks New CEO, Facing Sales Slump and Tariffs -- 3rd Update

8 Apr 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 Apr 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8 Apr 2025, 20:40 UTC

Earnings

BYD Stock Soars. It's Catching Up to Tesla in Yet Another Way. -- Barrons.com

8 Apr 2025, 20:28 UTC

Earnings

Sandstorm Gold: Will Release 1Q Results on May 6 After Markets Close >SSL.T

8 Apr 2025, 20:28 UTC

Earnings

Sandstorm Gold: During Three Mos Ended March 31, Realized Record Preliminary Revenue of $50.1M (20,316 Attributable Gold Equivalent Ounces and $42.8M in Rev for the Comparable Period in 2024) >SSL.T

8 Apr 2025, 20:28 UTC

Earnings

Sandstorm Gold: Record Preliminary Total Sales, Royalties, Income From Other Interests of $54.1M for Three Mos Ended March 31 ($42.8M in Total Sales, Royalties, Income From Other Interests for Comparable Period in 2024) >SSL.T

8 Apr 2025, 20:28 UTC

Earnings

Sandstorm Gold: During Three Mos Ended March 31, Sold Approximately 18,500 Attributable Gold Equivalent Ounces >SSL.T

8 Apr 2025, 20:14 UTC

Top News

U.S. Stocks Retreat as Optimism Over Trade Talks Fades -- WSJ

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

187.45% upside

12 Months Forecast

Average 75.83 USD  187.45%

High 100 USD

Low 53 USD

Based on 14 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

13

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

N/A / 28.475Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

173 / 385 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.